In this interview, we talk with Professor Kathryn Torok (UPMC & University of Pittsburgh Scleroderma Center, University of Pittsburgh, Pittsburgh, PA, USA) around CD34-selected peripheral blood ASCT in patients with juvenile-onset systemic sclerosis (NCT03630211).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Autologous Stem Cell Transplantation with CD34-Selected Peripheral Blood Stem Cells in Patients with Treatment-Resistant Juvenile-Onset Systemic Sclerosis.’ (ABSTRACT NUMBER: 0778) was presented at the ACR Convergence 2021, 3-9 November 2021.
Questions
- What is known about the clinical utility of autologous stem cell transplant (ASCT) in patients with aggressive and recalcitrant juvenile-onset systemic sclerosis? (0:16)
- Could you tell us a little about the reduced intensity conditioning protocols you have developed using CD34-selected peripheral blood ASCT? (2:48)
Disclosures: Kathryn Torok has nothing to disclose in relation to this video.
Correspondence: Kathryn Torok, MD, Associate Professor of Pediatrics, Division of Pediatric Rheumatology, UPMC & University of Pittsburgh Scleroderma Center, University of Pittsburgh |UPMC Children’s Hospital of Pittsburgh, 4401 Penn Ave, Pittsburgh, PA 15224, Tel: (412) 692-5081 | Fax: (412) 692-5054 | kathryn.torok@chp.edu
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual ACR Convergence 2021.
